Introduction {#s0001}
============

Rotavirus infection (mostly caused by Group A viruses) is a major, vaccine-preventable disease in humans worldwide. Although the infection is ubiquitous in all ages, it is most significant, and often quite severe, in infants and young children. The burden of severe rotavirus illness and death is greatest in children from countries with low socio-economic status, with more than 80% of rotavirus-related deaths estimated to occur in Asia and sub-Saharan Africa.[@cit0001]

India, in particular, has a large population at risk of clinically significant rotavirus gastroenteritis: of the 1.2 billion population, 11% are aged \<5 years. In 2008, diarrhea attributable to rotavirus infection resulted in 453,000 deaths (95% CI 420,000--494,000) worldwide in children aged \<5 years, representing 37% of deaths attributable to diarrhea and 5% of all deaths in children aged \<5 years.[@cit0002] Five countries accounted for more than half of all deaths attributable to rotavirus infection: Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan, with India alone accounting for 22% of deaths (98,621 deaths).[@cit0002]

Rotavirus Serotypes are specified by 2 outer capsid proteins, VP4 and VP7.[@cit0003] The protease-sensitive protein VP4 defines P genotypes and the glycoprotein VP7 defines the G genotypes.[@cit0004] As the 2 genes that determine G-types and P-types can be passed on separately to progeny viruses, different combinations are found.[@cit0005]

Of the 24 G genotypes and 33 P genotypes described to date, 12 G and 15 P genotypes are known to infect humans.[@cit0006] Genotype G1P\[8\], G2P\[4\], G3P\[8\], G4P\[8\] and G9P\[8\] cause over 90% of rotavirus disease worldwide. Genotype G9 strains were initially identified in the USA and Japan in 1983--1984.[@cit0008] The G9 strains re-emerged in the early to mid-1990s, and the global prevalence has increased, such that G9 in combination with P\[8\], P\[4\] and P\[6\] have been detected in over 55 countries in Europe, Asia, Africa, South and North America, and represent the dominant genotype in some regions over the past decade.[@cit0010]

However, G1 has remained the predominant strain in India, while G9 and G12 are emerging as new strains.[@cit0012] Interestingly, recent studies have indicated that the G9 strain is mainly confined to the eastern part of India.^13^Current available data indicates fluctuations in rotavirus G/P-type that also vary by geography and season, as well as the emergence of unusual types, such as G5, G6, G8, G9, G12, and P\[6\] for reasons that are poorly understood. This makes accurately predicting serotype circulation and understanding the clinical implications of the serotype changes a challenge.[@cit0011]

A pentavalent vaccine containing 5 separate viruses that expressed either human G1, 2, 3, or 4 VP7s, and a human P(8) VP4 on the bovine WC3 backbone was developed and licensed after extensive clinical evaluation, by Merck Pharmaceuticals as RotaTeq®.[@cit0014] Using a wild-type human rotavirus isolate P1A\[8\]G1 strain which represented the most common human rotavirus VP7 and VP4 antigens and attenuated by multiple tissue culture passages, a monovalent oral rotavirus vaccine was developed by GlaxoSmithKline Biologicals, as Rotarix®.[@cit0015] Both Rotarix and RotaTeq vaccines have since demonstrated the efficacy in developing countries, leading to the WHO recommendation for their widespread introduction.[@cit0016]

At the time of this study both Rotarix and Rotateq were available in the private market in India and had not been included in the Indian National Immunization Schedule. The subjects involved in this study were from suburban and rural population and depended upon the study hospitals to provide vaccination in compliance with the Indian National Immunization Schedule. None of the available Rotavirus vaccines was being used in the study population.

Both Rotateq and Rotarix have demonstrated heterotypic protection in the efficacy studies but the level of protection is lower than that seen for the homotypic strains, therefore it is important to keep a track of new emerging strains and severity associated with them.

As there are still a number of new rotavirus vaccines under development globally, the results from this study may help in understanding the need for inclusion of rotavirus strains depending upon the severity of clinical implications associated with particular serotypes.

Earlier, we reported an estimate of the burden of rotavirus gastroenteritis in children aged \<5 years, taking into account rotavirus positivity, genotypic distribution and seasonality in different regions of India.[@cit0013] One of the objectives of this surveillance was to categorize rotavirus-associated diarrhea by clinical severity and associated serotypes. Given the epidemiological variability in rotavirus G-type distribution, and the spectrum of clinical manifestation of rotavirus disease, we examined the possible relationship between epidemiologic and clinical features of rotavirus gastroenteritis and G types.

Results {#s0002}
=======

Stool samples (n = 2051) were systematically collected from 4,711 children aged \<5 years and were tested for VP6 antigen. Of the 541 rotavirus VP6 antigen positive stool samples, the predominant rotavirus genotypes reported were G1 (38%), G2 (18%), G9 (18%) and G12 (9%). A large number of children (25%) had mixed infections. In order to directly compare the G type strains, and eliminate any bias in reporting, all mixed and non-typeable samples were excluded. A total of 377 positive stool samples were included in our analysis. Median of maximum number of stools collected was 9 in any 24 hours.

[Figure 1](#f0001){ref-type="fig"} shows the distribution of rotavirus strains by diarrhea severity. G1-specific diarrhea was reported in 174 children, with very severe diarrhea reported in 59 (33.9%), severe diarrhea in 104 (59.8%), moderate diarrhea in 10 (5.8%) and mild diarrhea in 1 (0.5%). G2-specific diarrhea was reported in 95 subjects, with very severe diarrhea reported in 26 (27.4%) children, severe diarrhea in 46 (48.4%), moderate diarrhea in 21 (22.1%) and mild diarrhea in 2 (2.1%). G9-specific diarrhea was reported in 86 subjects, with very severe diarrhea reported in 47 (54.5%) children, severe diarrhea in 29 (33.6%), moderate diarrhea in 9 (10.3%) and mild diarrhea in 1 (1.6%). G12-specific diarrhea was reported in 22 children, with very severe diarrhea reported in 9 (40.9%), severe diarrhea in 13 (59.1%); there were no cases of moderate or mild diarrhea. These differences are confirmed with the observed median of the Vesikari score per genotype (*p*-value = 0.0002). Diarrhea due to G3 strain was not seen, and the G4 strain was found from one child, therefore neither of these strains were considered for direct comparison. Figure 1.Reported rotavirus strains and associated diarrhea severity (based on Vesikari grading scale).

[Table 1](#t0001){ref-type="table"} compares the demographic details of the infants who experienced G1, G2, G9 and G12 gastroenteritis, as well as their clinical characteristics. There was significant difference in the mean age at hospitalization of the children. The greatest number of children reporting vomiting for more than 3 days was in the G9 group (58.8%), followed by G12 (40.9%) and G2 (26.3%), while the lowest number of subjects was in G1 group (24.7%). Dehydration was relatively higher in the G12 (90.9%) and G9 groups (88.4%) compared with the 2 other groups, G1 (78.7) and G2 (64.2%). High number of loose stools in 24h is more frequent in subjects with G1. The association between genotype and high number of loose stools in 24h, vomiting for more than 3 days and Veskari score is confirmed by the multivariate approach, once adjusting on the age effect. Table 1.Rotavirus serotypes associated demographic and clinical characteristics. Serotype VariableG1 (n = 174)G2 (n = 95)G9 (n = 86[^\*^](#t1fn0001){ref-type="fn"})G12 (n = 22)*p*-value[^\*\*^](#t1fn0002){ref-type="fn"}Sex; n (%)      Female47 (27.0)37 (38.9)35 (40.7)7 (33.3)0.0876 Male127 (73.0)58 (61.1)51 (59.3)14 (66.7) Mean age at hospitalization (months)13.314.217.011.70.0305 Loose stools for \>6 days n (%)38 (21.8)24 (25.3)12 (14.1)1 (4.55)0.0673 Loose stools for \>3 days n (%)123 (70.7)69 (72.6)61 (71.8)18 (81.8)0.7477 Six or more loose stools within 24h n (%)145 (83.3)56 (58.9)59 (69.4)16 (72.7)0.0002Duration of vomiting \>3 days n (%)43 (24.7)25 (26.3)50 (58.8)9 (40.9)\<0.0001 Three or more episodes of vomiting within 24h n (%)101 (58.0)52 (54.7)46 (54.2)13 (59.1)0.9093Temperature \>39^°^C n (%)10 (5.7)6 (6.3)2 (2.3)1 (4.5)0.5884 Dehydration \>6% of body weight n (%)137 (78.7)61 (64.2)76 (88.4)20 (90.9)0.0004 Vesikari severity score, mean (sd)14.6 (2.5)13.3 (3.4)15.2 (3.2)15.0 (2.7)0.0002[^2][^3]

Discussion {#s0003}
==========

Our study shows that children hospitalized with G1 serotype infection generally had less severe diarrhea than those with the new emerging strains, G9 and G12. These data are consistent with studies from 3 Latin American countries, which indicate that serotype G9 infection is associated with more-severe disease than serotype G1 infection.[@cit0017] Similar trends were reported in studies conducted in the United Kingdom, which showed that the proportion of G9 strains (P\[6\] and P\[8\]) was significantly higher among patients admitted to the hospital than those treated at the community level.[@cit0018] Another hospital-based study conducted in London found a higher proportion of cases requiring intravenous rehydration among those infected with the G9 strain, compared with other common G types.[@cit0019] In contrast, while a study from Indonesia reported greater clinical severity with G2 serotype among hospitalized subjects due to rotavirus gastroenteritis,[@cit0020] 2 studies conducted in Italy and the United States did not find differences in disease severity between patients with G9 infection and patients with infection due to other G types.[@cit0021] Difference in severity may be traced back to the origin of G9 and G12 strains, which goes back to mid-nineties in Europe and United states while it is more recent in India.[@cit0010]

Differences in disease severity may be caused not only by variation in virulence, but by the introduction of new strains. When a rotavirus strain is newly introduced into a community, more frequent and more-severe cases are anticipated than those associated with the common rotavirus strains because of a lack of maternal antibodies, and lack of prior exposure to this specific rotavirus type. Clinical determinants, such as duration of vomiting and dehydration, are more frequently observed with G9 and G12 strains, which may contribute to the higher severity associated with these strains.

One limitation of this analysis is that the surveillance protocol was set up to capture only acute hospitalized gastroenteritis cases, which only represents the trends observed in children who were already more sick than those who may have been either managed in the community, or who may not have been sick enough to require hospitalization. This limitation suggested the need for a further research involving both hospitalized and non-hospitalized cases of rotavirus gastroenteritis. In addition, mixed infections and non-typable samples, which form a major part of the overall disease burden, were not considered for clinical severity comparisons.

In summary, G9 and G12 serotype associated rotavirus gastroenteritis infections are on the increase and represent 2 important emerging serotypes in children younger than 5 years in India.[@cit0012] Our findings suggest that rotavirus gastroenteritis infections caused by G9 and G12 (emerging serotypes) are associated with clinically more-severe disease than infections with G1 and G2 serotypes, which are still the most common serotypes seen in the Indian population.[@cit0013]

This study also highlights the importance of including the epidemiologically emerging rotavirus strains in future multivalent rotavirus vaccines. This would help to make the vaccines regionally more specific, broaden the scope of vaccine coverage and enhance the ability of the vaccine to provide a secured homotypic protective response to the potentially severe serotypes.

Patients and methods {#s0004}
====================

Study centers and duration {#s0004-0001}
--------------------------

The surveillance study was conducted to capture the severity and strains of rotavirus gastroenteritis in children aged \<5 years at 12 medical school centers in India, from April 2011 to July 2012. ([Fig. 2](#f0002){ref-type="fig"}) Figure 2.Distribution of sites across India.

Inclusion criteria {#s0004-0002}
------------------

Children \<5 years of age presenting with severe acute gastroenteritis (defined by the passage of ≥3 looser than normal stools, with or without vomiting during the preceding 24 hour period) and requiring hospitalization for at least 6 hours were eligible for inclusion in this study. An approved, informed consent statement, for obtaining stool samples, was obtained from the parents/legally acceptable representatives of the children, as per local ethical and regulatory requirements. Upon obtaining consent, the children were included in the study and a stool sample obtained. Children older than 60 months, and those younger than 60 months but not requiring hospitalization for at least 6 hours, or whose parents did not consent for stool sampling were not included in the study.

Clinical assessment {#s0004-0003}
-------------------

Parameters for clinical assessment of diarrhea severity included: time of onset, duration and maximum number of episodes of diarrhea and vomiting, intensity of fever and dehydration. These parameters were recorded in a case report form. Severity of diarrhea was assessed using the Vesikari scoring system.[@cit0023] As per the Vesikari score, a grade of 0--5 was considered as mild, 6--10 as moderate, 11--15 as severe and \>16 as very severe.

Stool specimen collection {#s0004-0004}
-------------------------

Approximately 5 ml of stool sample was collected from every alternate children if available, in stool containers either on the day of presentation to hospital or within 48 hours of hospital admission to avoid confounding from hospital-acquired infections. All the stool specimens were stored at −20°C until testing, and sufficient care was taken to avoid freeze--thaw cycles.

Detection of rotavirus {#s0004-0005}
----------------------

All the stool samples were tested for rotavirus VP6 antigen using a commercial enzyme immunoassay kit (Premier Rotaclone Qualitative EIA, Meridian Bioscience Inc., Cincinnati, USA) at the respective study centers, in duplicate, and with appropriate controls. Rotavirus VP6 antigen positive stool samples were sent for genotyping at a Central Laboratory at the Department of Gastrointestinal Sciences, Christian Medical College, Vellore, India.

Strain surveillance and characterization {#s0004-0006}
----------------------------------------

Genotyping was performed using methods that have been previously published and considered standard.[@cit0013]^,[@cit0024]^

Statistical analysis {#s0004-0007}
--------------------

Diarrheal hospital log books, case report forms and genotype result reports were used to generate the data for analysis. All logs and forms were scrutinized for completeness, and the data were entered into Excel 2012 (Microsoft, Redmond, WA, USA). Analysis was performed using QuickCalcs, version 5 (GraphPad Software, Inc., La Jolla, CA, USA). Stool samples were collected as continuous variable. Tests of proportion, Chi-squared and Fisher exact tests were applied for qualitative data, and Wilcoxon rank-sum test for quantitative data. A multinomial logistic regression was used as a multivariate approach. P values \<0.05 were considered to be statistically significant.
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[^1]: Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/khvi.](http://www.tandfonline.com/khvi)

[^2]: one subject with serotype G9 did not answer all items.

[^3]: Chi-square or Fisher exact test for qualitative items, Wilcoxon Rank Sum for quantitative items.
